Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia

Authors

William Maier, Emory University, Georgia
David Gordon, Emory University, Georgia
Robert Howard, Emory University, Georgia
Mansoor Saleh, Aga Khan UniversityFollow
Stephen Miller, Emory University, Georgia
Jefrey Lieberman, Emory University, Georgia
Pamela Woodlee, Emory University, Georgia

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

Seven patients with thrombocytopenia and systemic lupus erythematosus were treated with intravenous (IV) doses of human immunoglobulin to assess clinical response and to examine the mechanism of action of IV immunoglobulin in these patients. Five of 7 patients had a >50% increase in their platelet counts. Four of these patients had a sustained benefit of at least 6 months duration. The initial effectiveness of IV immunoglobulin therapy was not dependent on the reduction of levels of circulating platelet-binding IgG or circulating immune complexes.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Arthritis & Rheumatism

DOI

https://doi.org/10.1002/art.1780330825

Recommended Citation

Maier, W., Gordon, D., Howard, R., Saleh, M., Miller, S., Lieberman, J., Woodlee, P. (1991). Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis & Rheumatism, 33(8), 1233-1239.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/154